共 39 条
- [31] C. E. R. A. provides stable haemoglobin (Hb) levels in ckd patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthlyNEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 411 - 411Mann, JohannesLocatelli, FrancescoSulowicz, WladyslawNissenson, AllenPortoles, JoseLevin, NathanDel Aguila, MichaelDougherty, Frank C.
- [32] SWITCH TO LOW DOSE C. E. R. A. MAINTAINS HEMOGLOBIN (HB) LEVELS IN NON DIALYSIS CHRONIC KIDNEY DISEASE (CKD): A MULTICENTRIC PROSPECTIVE STUDY IN ITALYNEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 137 - 137Minutolo, RobertoCozzolino, MarioDi Iorio, BiagioPolito, PasqualeSantoro, DomenicoManenti, FlaviaNappi, FeliceFeriozzi, SandroConte, GiuseppeDe Nicola, Luca
- [33] Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapyTRIALS, 2007, 8Hirsh, VeraGlaspy, JohnMainwaring, PaulManegold, ChristianRamlau, RodrygEid, Joseph E.
- [34] Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapyTrials, 8 (1)Vera HirshJohn GlaspyPaul MainwaringChristian ManegoldRodryg RamlauJoseph E Eid
- [35] Effect of-55C/T Polymorphism of Uncoupling Protein 3 Gene on Risk for New-Onset Diabetes in Chinese Peritoneal Dialysis Patients: A Prospective Cohort StudyBLOOD PURIFICATION, 2021, 50 (06) : 857 - 864Chen, YunDai, ShuqiShang, DaGe, XiaolinXie, QionghongHao, Chuan-MingZhu, Tongying
- [36] NGM313, a Novel Once-Monthly Activator of β-Klotho/FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Nonalcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin Resistant Patients with NAFLDHEPATOLOGY, 2018, 68 (06) : 1460A - 1460ADePaoli, AlexShankar, SudhaBashir, Mustafa R.Baxter, Bryan A.Van PhungYan, Andrew Z.Rossi, Stephen
- [37] C. E. R. A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52-week study of patients with chronic kidney disease (CKD) not on dialysisNEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 412 - 412Walker, RowanMacdougall, Iain C.Levin, AdeeraKessler, MicheleNoble, SylviaBurgos-Calderon, RafaelBeyer, UlrichDougherty, Frank C.
- [38] Continuous Erythropoietin Receptor Activator (C. E. R. A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomized, multicentre, multiple-dose, phase II study (vol 60, pg 1687, 2006)INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (10) : 1776 - 1777Huang, C-CHuang, J-J
- [39] Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Liu, Joyce F.Fu, SiqingRichardson, Gary EdwardVranjes, ZivkoMeniawy, TarekShannon, Catherine M.Hamilton, Erika P.Blank, Stephanie V.Mathews, Cara AmandaAlidzanovic, JasminaRuseva, Rossitza KrastevaShi, QingHarismendy, OlivierPtaszynski, Ann M.Westin, Shannon NevilleMeric-Bernstam, FundaThaker, Premal H.